# Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

> **NCT05616013** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 507 (actual)

## Conditions studied

- Obesity
- Obese
- Overweight or Obesity

## Interventions

- **BIOLOGICAL:** Bimagrumab
- **DRUG:** Semaglutide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05616013
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-16
- **Primary completion:** 2024-05-16
- **Final completion:** 2025-06-14
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05616013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05616013, "Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05616013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*